These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 7940784)

  • 1. Renal allograft infarction is a cause of early kidney transplant loss in the cyclosporine A era.
    Andrés A; Mazuecos A; Morales JM; Praga M; Martinez MA; Usera G; Araque A; Rodicio JL
    Transplant Proc; 1994 Oct; 26(5):2544-5. PubMed ID: 7940784
    [No Abstract]   [Full Text] [Related]  

  • 2. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
    Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B
    Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated acute rejection in renal allograft.
    Han DJ; Yoon HS; Lee HM
    Transplant Proc; 1996 Jun; 28(3):1455. PubMed ID: 8658738
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal transplantation in children less than 5 years of age: a single center experience in the cyclosporine era.
    Tydén G; Berg U; Bohlin AB
    Transplant Proc; 1994 Feb; 26(1):93-4. PubMed ID: 8109039
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute vascular rejection with hemolytic uremic syndrome in kidneys from non-heart-beating donors: associated with secondary grafts and early cyclosporine treatment?
    Schlumpf R; Candinas D; Weder W; Röthlin M; Zollinger A; Bleisch J; Retsch M; Largiadèr F
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1518-21. PubMed ID: 8442172
    [No Abstract]   [Full Text] [Related]  

  • 7. The influence of cold ischemia and donor age on renal allograft outcome in the cyclosporine era.
    Cacciarelli TV; Sumrani N; DiBenedetto A; Hong JH; Sommer BG
    Transplant Proc; 1992 Oct; 24(5):2044-5. PubMed ID: 1412966
    [No Abstract]   [Full Text] [Related]  

  • 8. Graft loss associated with late humoral rejection after renal transplantation.
    Sun Q; Li L
    Clin Transpl; 2006; ():521-5. PubMed ID: 18365417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of graft nephrectomy in pre-cyclosporine and cyclosporine era.
    Adhikary SD; Viswaroop SB; Kekre NS; Gopalakrishnan G
    Urol Int; 2008; 80(1):80-3. PubMed ID: 18204239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different trends in immunosuppression: 10 years' experience with cyclosporine after living related donor renal transplantation.
    Bakr MA; Sally S; Foda MA; Sobh MA; el-Sherif AK; Ghoneim MA
    Transplant Proc; 1994 Dec; 26(6):3163-6. PubMed ID: 7998104
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine monotherapy in children: long-term effect.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2610-6. PubMed ID: 7940813
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors affecting compliance with cyclosporine in adult renal transplant patients.
    Sketris I; Waite N; Grobler K; West M; Gerus S
    Transplant Proc; 1994 Oct; 26(5):2538-41. PubMed ID: 7940782
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal transplantation in cyclosporine-treated recipients at the Singapore General Hospital.
    Vathsala A; Woo KT
    Clin Transpl; 1999; ():189-97. PubMed ID: 11038637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W; Sherrill B; Brennan DC; Lowell J; Schnitzler M
    Transplantation; 2003 Dec; 76(12):1686-90. PubMed ID: 14688516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients.
    Schroeder TJ; Hariharan S; First MR
    Transplant Proc; 1994 Oct; 26(5):2787-90. PubMed ID: 7940878
    [No Abstract]   [Full Text] [Related]  

  • 17. IgA nephropathy in renal transplant recipients: is it a significant cause of allograft failure?
    Park SB; Joo I; Suk J; Cho WH; Park CH; Kim SP; Park KK; Kim HC
    Transplant Proc; 1996 Jun; 28(3):1540-2. PubMed ID: 8658777
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictors for late allograft nephrectomy in the cyclosporine era.
    Sumrani N; Daskalakis P; Hong JH; Markell M; Sommer BG
    Transplant Proc; 1992 Oct; 24(5):1747-9. PubMed ID: 1412823
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of acute rejection to renal allograft loss from chronic rejection.
    Sumrani N; Cacciarelli TV; Georgi B; Daskalakis P; Miles AM; Goldberg K; Hong JH; Sommer BG
    Transplant Proc; 1993 Jun; 25(3):2259-60. PubMed ID: 8516892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.